


### REMARKS

In reviewing the file prior to payment of the issue fee, Applicants have noted that current sequence listing does not comply with 37 C.F.R. 1.821-1.823. In order to bring the application into compliance, Applicants submit herewith a substitute paper sequence listing, a CRF of the substitute sequence listing, and a Statement Under 37 C.F.R. 1.825. Applicants respectfully request that the substitute paper sequence listing be incorporated at the end of the specification.

The substitute paper sequence listing submitted herewith has been amended to correct bibliographic information and to correct defects as to form for SEQ ID Nos. 41-48. As such, Applicants contend that no new matter has been added. To aid the Examiner in reviewing the amendments, Applicants also submit herewith a partial copy of the sequence listing marked to show changes made to the bibliographic information and SEQ ID Nos. 41-48.

Applicants believe that no fee is due in association with this submission. If the Applicants are in error, the Commissioner is hereby authorized to charge any underpayment or credit any overpayment that may occur during the pendency of this application to Deposit Account No. 01-0535.

Respectfully submitted,

  
James E. Butler, Ph.D.  
Registration No. 40,931

AMYLIN PHARMACEUTICALS, INC.  
9360 Towne Centre Drive  
San Diego, CA 92121  
(858) 458-8564